Test Price
2,800 AEDโ Home Collection Available
CACNA1S Gene Hypokalemic Periodic Paralysis Type 1 Genetic Test โ Dubai, UAE | 2800 AED
Executive Summary & Core Metrics
- โ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next-generation sequencing and Sanger confirmation.
- โ Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- โ Clinical Guidance: Telephonic post-test clinical interpretation support by DHA-licensed genetics specialists.
- โ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CACNA1S test uses next-generation sequencing to detect pathogenic variants in the CACNA1S gene, the definitive cause of hypokalemic periodic paralysis type 1. This UAE-based molecular assay delivers high diagnostic accuracy with a 3- to 4-week turnaround, enabling personalized neurological management.
| Feature | Our Test (NGS + Confirmation) | Alternative (Single-Gene Sanger) |
|---|---|---|
| Methodology | NGS panel with Sanger validation | Sanger sequencing of exon regions only |
| Sensitivity | 99.9% (all variant types) | ~95% (misses deep intronic/CNV variants) |
| Turnaround | 3โ4 weeks | 4โ6 weeks |
| Regulatory Alignment | Full DHA/MOHAP & ISO 15189 standards | Partial; may lack CAP/ISO oversight |
Physician Insight & Safety Protocols
โAs a clinical geneticist, I understand that genetic testing can raise deep concerns. Confirming a CACNA1S mutation is not just a diagnostic endpoint โ it opens the door to tailor-made preventive strategies and medication adjustments that can dramatically reduce attack frequency. Results must always be correlated with your complete clinical picture.โ
Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication & Clinical Oversight
Do not discontinue prescribed medication without consulting your doctor
Genetic findings may refine therapy, but abrupt changes can trigger life-threatening episodes. Always discuss results with your managing physician before any adjustment.
Exclusion Criteria & ER Red Flags
- Sudden severe muscle weakness or paralysis
- Difficulty breathing or swallowing
- Irregular heartbeat, palpitations, or chest pain
- Acute potassium imbalances (hypo- or hyperkalemia)
- Test not indicated for unstable or critically ill patients
Patient FAQ & Clinical Guidance
1. What is hypokalemic periodic paralysis type 1?
The test detects CACNA1S mutations responsible for hypokalemic periodic paralysis, ensuring precise diagnosis and treatment guidance.
2. How accurate is this genetic test?
Our NGS test achieves 99.9% diagnostic sensitivity with Sanger confirmation, guaranteeing clinically actionable results.
3. Will my insurance cover the test cost?
We offer direct billing verification via WhatsApp to instantly confirm insurance coverage for the 2800 AED test.
4. How is the sample collected?
Standard peripheral whole blood (3โ5 mL in EDTA tube) is collected by our VIP mobile phlebotomy service at your home or office, or at any DNA Labs UAE collection center. Cold-chain transport ensures sample integrity.
5. When will I receive my results?
Results are typically ready within 3โ4 weeks (21โ28 calendar days). A confidential electronic report is shared with you and your referring physician.
UAE Regulatory & Data Privacy Adherence
Comprehensive Legal Framework
All genetic testing at DNA Labs UAE is conducted in strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, stored securely, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | CACNA1S Gene Hypokalemic Periodic Paralysis Type 1 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks (21โ28 calendar days) |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | G72.3 (Periodic paralysis) |
| LOINC Code | 21636-6 (CACNA1S gene mutation analysis) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians